Tender Offer | ₹47.00 Crores | Listed at BSE, NSE | Thu, Apr 30, 2026 - Thu, May 7, 2026
Windlas Biotech Ltd Buyback is a tender offer for the repurchase of up to 0.05 crore equity shares, representing 2.23% of the total paid-up equity share capital at a buyback price of ₹1000 per share with a face value of ₹5 per share, aggregating to ₹47.00 crores.
The record date for determining eligible shareholders is Apr 24, 2026. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on Apr 30, 2026 and closes on May 7, 2026, with the last date for receipt of tender forms being May 7, 2026.
The finalisation of buyback acceptance is expected on May 13, 2026, followed by settlement of bids on Apr 14, 2026.
Fintellectual Corporate Advisors Pvt.Ltd. is the Manager to the Buyback, MUFG Intime India Pvt.Ltd. is the Registrar and SMC Global Securities Limited is the Registered Broker to the Buyback.
Investors are advised to refer to the Windlas Biotech Ltd Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Thu, Apr 30, 2026
Offer Closing Date
Thu, May 7, 2026
Buyback Price
₹1000 per share
Record Date
April 24, 2026
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 1 : 18 | 97,342 |
| General Category | 1 : 18 | 3,72,658 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|
| Assets | 760.45 | 626.21 |
| Total Income | 777.90 | 644.42 |
| Profit After Tax | 60.99 | 58.19 |
| Amount in ₹ Crore | ||
Windlas Biotech Limited is a pharmaceutical company engaged in contract development and manufacturing (CDMO), along with the production and marketing of generic and OTC products. The company focuses on providing end-to-end services, including product development, manufacturing, and commercialization for various pharmaceutical companies.
The company operates through key segments such as CDMO services, trade generics, and exports. It manufactures a wide range of dosage forms including tablets, capsules, syrups, and sachets, catering to multiple therapeutic areas like anti-diabetic, cardiovascular, gastrointestinal, and respiratory. Windlas Biotech has built strong relationships with numerous domestic and international pharma companies, supplying products across several global markets.
With state-of-the-art manufacturing facilities and adherence to global quality standards, Windlas Biotech emphasizes innovation, affordability, and scalability. The company continues to expand its capabilities in complex generics and specialized formulations, positioning itself as a reliable partner in the pharmaceutical manufacturing ecosystem.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Mar-2026 | 785.00 | 699.35 | 742.00 |
| Feb-2026 | 967.00 | 748.95 | 805.78 |
| Jan-2026 | 962.00 | 735.00 | 796.51 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Mar-2026 | 786.00 | 697.40 | 740.88 |
| Feb-2026 | 928.50 | 746.00 | 805.70 |
| Jan-2026 | 950.00 | 735.30 | 795.72 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Windlas Biotech Ltd
40/1,
Mohabewala Industrial Area
Dehradun, Uttarakhand, 248110
Lead Manager(s)
Registered Broker
The Windlas Biotech Buyback 2026 opens on April 30, 2026, and closes on May 7, 2026.
The Windlas Biotech Buyback 2026 last day to buy is not available as of now.
The Windlas Biotech Buyback 2026 is a Tender Offer.
Windlas Biotech Buyback 2026 Schedule
| Buyback Opening Date | April 30, 2026 |
| Buyback Closing Date | May 7, 2026 |
| Last Date for receipt of Tender Forms | May 7, 2026 |
| Finalisation of Buyback Acceptance | May 13, 2026 |
| Last Date for settlment of bids | April 14, 2026 |
| Last Date for Extinguishment of Shares | May 25, 2026 |
The Windlas Biotech Buyback 2026 is being offered at Rs ₹1000 per share.
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 1 : 18 | 97,342 |
| General Category | 1 : 18 | 3,72,658 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
The issue size of Windlas Biotech Buyback 2026 is 4,70,000 equity shares at ₹1000 per share aggregating up to ₹47.00 Crores.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Windlas Biotech Buyback 2026 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
